One of the principal tasks of an oncologist is to determine whether to administer, reduce the dose, or hold chemotherapy on the basis of patient characteristics, organ function, and toxicities. These ...

MALVERN, Pa., March 25, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life ...

As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...

The FDA has granted an Emergency Use Authorization (EUA) to VitalConnect that allows its VitalPatch wearable sensor to further monitor patients undergoing COVID-19 treatment. As per the agency's ...

Implementation of dietary education within a multidisciplinary team approach to improve treatment accuracy and efficiency in prostate cancer external beam radiation therapy. This is an ASCO Meeting ...

NEW YORK--(BUSINESS WIRE)--AccurKardia, a software company that provides clinical-grade, device agnostic, automated ECG (“electrocardiogram”) analytics, today announced the first study showcasing the ...

CredibleMeds, a valuable resource for prescribing physicians, now includes information from FDA drug labels to inform prescribers of any ECG monitoring recommendations, warnings for use in congenital ...

Now, in the full, published report, Woosley, Rodriguez, and colleagues describe how variations in menstrual cycle appear to effect the development of torsades de pointes in women taking ibutilide.

OBJECTIVE: To examine the effect of cisapride on the corrected QT (QTc) interval in infants over a 14-day period. STUDY DESIGN: A prospective cohort study of infants receiving cisapride (0.8 mg/kg per ...

The MERIDIAN M110 Fetal Monitoring System is indicated for use on women who are at ≥ 37 completed weeks, in labor, with singleton pregnancies using surface electrodes on the maternal abdomen. The ...

Silver Spring, MD - The FDA's Cardiovascular and Renal Drugs Advisory Committee has ruled that the clinical trials conducted by Bayer/GlaxoSmithKline for its erectile dysfunction drug, vardenafil ...